| Item Type | Name |
|
Concept
|
Acylation
|
|
Concept
|
Acetates
|
|
Concept
|
Age Factors
|
|
Concept
|
Attention
|
|
Concept
|
Arteriovenous Malformations
|
|
Concept
|
Acrocephalosyndactylia
|
|
Concept
|
Acidosis
|
|
Concept
|
Adenosine Triphosphatases
|
|
Concept
|
Brain Damage, Chronic
|
|
Concept
|
Hypoxia, Brain
|
|
Concept
|
Benzamides
|
|
Concept
|
Aspirin
|
|
Concept
|
Blood Glucose
|
|
Concept
|
Biopsy
|
|
Concept
|
Botulism
|
|
Concept
|
Cell Membrane
|
|
Concept
|
Cell Division
|
|
Concept
|
Botulinum Toxins
|
|
Concept
|
Clone Cells
|
|
Concept
|
Cerebellum
|
|
Concept
|
Cerebral Ventricles
|
|
Concept
|
Cholinergic Fibers
|
|
Concept
|
Coma
|
|
Concept
|
Cochlear Implants
|
|
Concept
|
Codon
|
|
Concept
|
Cognition
|
|
Concept
|
Creatinine
|
|
Concept
|
DNA, Mitochondrial
|
|
Concept
|
Epilepsy
|
|
Concept
|
Cytochrome P-450 Enzyme System
|
|
Concept
|
Cell Fusion
|
|
Concept
|
Child, Preschool
|
|
Concept
|
Chromatography, High Pressure Liquid
|
|
Concept
|
Exotropia
|
|
Concept
|
Disease Susceptibility
|
|
Concept
|
Double-Blind Method
|
|
Concept
|
Dinitrophenols
|
|
Concept
|
Drug Evaluation, Preclinical
|
|
Concept
|
Dwarfism
|
|
Concept
|
Fatty Acids, Nonesterified
|
|
Concept
|
Indicators and Reagents
|
|
Concept
|
Fatty Acids
|
|
Concept
|
Fatty Acids, Unsaturated
|
|
Concept
|
Dicarboxylic Acids
|
|
Concept
|
Hippocampus
|
|
Concept
|
Electromyography
|
|
Concept
|
Embryo, Mammalian
|
|
Concept
|
Laurates
|
|
Concept
|
Fatty Acids, Volatile
|
|
Concept
|
Neuroma, Acoustic
|
|
Concept
|
Immunohistochemistry
|
|
Concept
|
Oxidative Phosphorylation
|
|
Concept
|
Pain
|
|
Concept
|
Mice, Inbred C57BL
|
|
Concept
|
Nerve Growth Factors
|
|
Concept
|
Neurilemmoma
|
|
Concept
|
Neuromuscular Junction
|
|
Concept
|
Synaptic Transmission
|
|
Concept
|
Neurofibromatosis 1
|
|
Concept
|
Oxidation-Reduction
|
|
Concept
|
Oleic Acids
|
|
Concept
|
Palmitates
|
|
Concept
|
Microscopy, Electron
|
|
Concept
|
Pseudarthrosis
|
|
Concept
|
Hybrid Cells
|
|
Concept
|
Hamartoma
|
|
Concept
|
Pyruvates
|
|
Concept
|
Quality of Life
|
|
Concept
|
Reye Syndrome
|
|
Concept
|
Rotenone
|
|
Concept
|
Cohort Studies
|
|
Concept
|
Mental Recall
|
|
Concept
|
Lactates
|
|
Concept
|
Spinal Neoplasms
|
|
Concept
|
Septal Nuclei
|
|
Concept
|
Humans
|
|
Concept
|
Lipid Metabolism, Inborn Errors
|
|
Concept
|
Incidence
|
|
Concept
|
Transcription, Genetic
|
|
Concept
|
Synaptic Vesicles
|
|
Concept
|
Tritium
|
|
Concept
|
Syndrome
|
|
Concept
|
Keto Acids
|
|
Concept
|
Lovastatin
|
|
Concept
|
Oculomotor Nerve Diseases
|
|
Concept
|
Oleic Acid
|
|
Concept
|
Meningioma
|
|
Concept
|
Immunocompromised Host
|
|
Concept
|
Mitochondria
|
|
Concept
|
Motor Endplate
|
|
Concept
|
Diabetic Ketoacidosis
|
|
Concept
|
Gene Expression
|
|
Concept
|
Case-Control Studies
|
|
Concept
|
Liver Transplantation
|
|
Concept
|
Meningeal Neoplasms
|
|
Concept
|
Mitochondria, Liver
|
|
Concept
|
NADH Dehydrogenase
|
|
Concept
|
8-Hydroxy-2-(di-n-propylamino)tetralin
|
|
Concept
|
Infarction, Middle Cerebral Artery
|
|
Concept
|
Angiogenesis Inhibitors
|
|
Concept
|
Neurofibromin 1
|
|
Concept
|
Noonan Syndrome
|
|
Concept
|
Auditory Brain Stem Implants
|
|
Concept
|
Cytochrome P-450 CYP4A
|
|
Concept
|
Consensus
|
|
Concept
|
Amino Acid Substitution
|
|
Concept
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
|
Concept
|
Mitogen-Activated Protein Kinase Kinases
|
|
Concept
|
Rats, Inbred Strains
|
|
Concept
|
RNA, Messenger
|
|
Concept
|
Cognitive Dysfunction
|
|
Concept
|
Spinal Cord Diseases
|
|
Concept
|
Subcellular Fractions
|
|
Concept
|
Valproic Acid
|
|
Concept
|
Tibial Fractures
|
|
Concept
|
Reproducibility of Results
|
|
Concept
|
Survival Rate
|
|
Concept
|
Cafe-au-Lait Spots
|
|
Concept
|
Hearing Loss
|
|
Concept
|
Executive Function
|
|
Concept
|
Brain Neoplasms
|
|
Concept
|
Cell Line
|
|
Concept
|
Clinical Trials as Topic
|
|
Concept
|
Follow-Up Studies
|
|
Concept
|
Foot
|
|
Concept
|
Learning
|
|
Concept
|
Neuroblastoma
|
|
Concept
|
Progesterone
|
|
Concept
|
Prospective Studies
|
|
Concept
|
Pyruvate Carboxylase
|
|
Concept
|
Thalamus
|
|
Concept
|
Databases, Factual
|
|
Concept
|
Neurofibromatosis 2
|
|
Concept
|
Neurofibromatoses
|
|
Academic Article
|
Do NF1 gene deletions result in a characteristic phenotype?
|
|
Academic Article
|
A child with neurofibromatosis-1 and a lumbar epidural arteriovenous malformation.
|
|
Academic Article
|
Late-onset neurofibromatosis in a liver transplant recipient.
|
|
Academic Article
|
Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1.
|
|
Academic Article
|
Decompressive hemicraniectomy in a 6-year-old male after unilateral hemispheric stroke. Case report and review.
|
|
Academic Article
|
Characterization of the binding sites for dicarboxylic acids on bovine serum albumin.
|
|
Academic Article
|
Development and characterization of clonal cell lines derived from septal cholinergic neurons.
|
|
Academic Article
|
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
|
|
Academic Article
|
Clinical manifestations and management of neurofibromatosis type 1.
|
|
Academic Article
|
Defect in fatty acid oxidation: laboratory and pathologic findings in a patient.
|
|
Academic Article
|
Environmentally induced differential amplification of mitochondrial populations.
|
|
Academic Article
|
Neoplasms with schwannian differentiation express transcription factors known to regulate normal schwann cell development.
|
|
Academic Article
|
Serum dicarboxylic acids in patients with Reye syndrome.
|
|
Academic Article
|
Hyperammonemia increases serotonin 1A receptor expression in both rat hippocampus and a transfected hippocampal cell line, HN2-5.
|
|
Academic Article
|
Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine.
|
|
Academic Article
|
Effect of Reye's syndrome serum on isolated chinchilla liver mitochondria.
|
|
Academic Article
|
Neuronal properties of clonal hybrid cell lines derived from central cholinergic neurons.
|
|
Academic Article
|
Effect of Reye's syndrome serum on the ultrastructure of isolated liver mitochondria.
|
|
Academic Article
|
Urinary dicarboxylic acids in Reye syndrome.
|
|
Academic Article
|
Omega-oxidation of monocarboxylic acids in rat brain.
|
|
Academic Article
|
In vitro microelectrode study of neuromuscular transmission in a case of botulism.
|
|
Academic Article
|
Cerebral malformations in Carpenter syndrome.
|
|
Academic Article
|
Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation.
|
|
Academic Article
|
Cognitive and psychosocial phenotype of young children with neurofibromatosis-1.
|
|
Academic Article
|
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
|
|
Academic Article
|
Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.
|
|
Academic Article
|
High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation.
|
|
Academic Article
|
Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials.
|
|
Academic Article
|
Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1.
|
|
Academic Article
|
Dural Ectasia in Neurofibromatosis 1: Case Series, Management, and Review.
|
|
Academic Article
|
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
|
|
Academic Article
|
Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1.
|
|
Academic Article
|
Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1.
|
|
Academic Article
|
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
|
|
Academic Article
|
Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.
|
|
Concept
|
Bevacizumab
|
|
Concept
|
Patient Reported Outcome Measures
|
|
Concept
|
NIMA-Related Kinases
|
|
Concept
|
In Vitro Techniques
|
|
Academic Article
|
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
|